No. It will not be a poster. But that being said they can (if the dataset matures by then) release the topline data to get some buzz around ASCO.
As you may remember (it has been posted here many times) there is a long process from submitting an abstract, to hearing that your abstract is accepted, to presenting the abstract (think about it in several months). So for it to be presented the trial would have to be completed months ago, which is not the case.
Alan's estimate is that the PD-1 + GR modulator cohort should have data available in mid-2019 / June, so if that happens I would expect topline around ASCO.
Lastly BTW not sure if your expectation that it moves the stock is warranted. CORT is a brick by brick story, not a single event story.....